A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications

International Journal of COPD

Volumn 12, Issue , 2017, Pages 1527-1537

  Ding, Bo ^a   Small, Mark ^b   Holmgren, Ulf ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Bronchodilators; COPD; GOLD group; Routine care; Symptom; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION DRUG THERAPY; CONSULTATION; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; FEMALE; GENERAL PRACTITIONER; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE CLASSIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PULMONOLOGIST; SCORING SYSTEM; CLASSIFICATION; CLINICAL PRACTICE; CLINICAL TRIAL; COST OF ILLNESS; DRUG EFFECTS; EUROPE; HEALTH CARE DISPARITY; HEALTH CARE SURVEY; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; REGISTER; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STANDARDS; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTHCARE DISPARITIES; HUMANS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85020027164     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S133793     Document Type: Article

References (32)

1. Miravitlles M, Worth H, Soler Cataluna JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 2017 [updated 2017]. Available from: http://www.goldcopd.org. Accessed November 18, 2016.
3. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–272.
4. Price D, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595–603.
5. Mullerova H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540.
6. Ahmed T, Steward JA, O’Mahony MS. Dyspnoea and mortality in older people in the community: a 10-year follow-up. Age Ageing. 2012; 41(4):545–549.
7. Lange P, Marott JL, Vestbo J, Nordestgaard BG. Prevalence of nighttime dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43(6):1590–1598.
8. Roche N, Small M, Broomfield S, Higgins V, Pollard R. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. COPD. 2013;10(6):679–686.
9. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 2016 [updated 2016]. Available from: http://www.goldcopd.org. Accessed October 30, 2016.
10. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 2014 [updated Jan 1, 2014]. Available from: http://www.goldcopd.org. Accessed October 30, 2016.
11. Jones P, Miravitlles M, van der MT, Kulich K. Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis. 2012;7:697–709.
12. Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011; 6:493–501.
13. Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904.
14. Koblizek V, Pecen L, Zatloukal J, et al. Real-life GOLD 2011 implementation: the management of COPD lacks correct classification and adequate treatment. PLoS One. 2014;9(11):e111078.
15. Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med. 2014;108(5):729–736.
16. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Over-treatment of COPD with inhaled corticosteroids–implications for safety and costs: cross-sectional observational study. PLoS One. 2013; 8(10):e75221.
17. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes–a means to understand. Curr Med Res Opin. 2008;24(11): 3063–3072.
18. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654.
19. Price D, Miravitlles M, Pavord I, et al. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. NPJ Prim Care Respir Med. 2016;26:16061.
20. Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217.
21. Seaman J, Leonard AC, Panos RJ. Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:89–97.
22. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106(7):989–997.
23. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;3:CD001104.
24. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2:CD002876.
25. Donohue JF, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65–74.
26. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
27. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294.
28. Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD–a systematic review and comment on trial methodology. Respir Res. 2011;12:107.
29. Wei YF, Kuo PH, Tsai YH, et al. Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with C. Int J Chron Obstruct Pulmon Dis. 2015;10:1951–1956.
30. Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract. 2014;15:42.
31. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23): 2222–2234.
32. Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066.